Holen Sie sich die Stockscreener-App
0.6876
1.12%
0.0076
Handel nachbörslich:
.62
-0.0676
-9.83%
Hepion Pharmaceuticals Inc Aktie (HEPA) Neueste Nachrichten
Hepion Pharmaceuticals Inc (CTVRP) Quarterly 10-Q Report - Quartzy
Pharma Two B and Hepion Pharmaceuticals, Inc. Announce Effectiveness of Registration Statement Related to Proposed Merger - The Manila Times
Pharma Two B and Hepion Pharmaceuticals, Inc. Announce - GlobeNewswire
Hepion & Pharma Two B Merger Advances: SEC Approves Key Registration for $HEPA Deal | HEPA Stock News - StockTitan
U.S. stocks higher at close of trade; Dow Jones Industrial Average up 0.67% - MSN
Non Alcoholic Fatty Liver Disease (NAFLD) Clinical Trials 2024: EMA, PDMA, FDA Approvals, Medication, Statistics, Drugs, Mechanism of Action, Route of Administration, and Companies by DelveInsight - The Globe and Mail
Will Hepion's AMBITION Be Fulfilled? - RTTNews
Phathom Pharmaceuticals (NASDAQ:PHAT) Shares Down 4% - MarketBeat
Hypha Labs, Inc. Releases Investor Presentation - AccessWire
Does Hyliion Holdings Corporation (NYSE: HYLN) Still Need To Convince Analysts? - Stocks Register
FluoRok raises US$ 9.8million for safety and sustainability of fluorochemical production - Indian Chemical News
FLO stock rated an Underperform by Exane BNP Paribas - Knox Daily
Barrow Hanley Mewhinney & Strauss LLC Purchases Shares of 898,419 Helios Technologies, Inc. (NASDAQ:HLIO) - MarketBeat
Hancock Whitney Corp Buys 10,920 Shares of PHINIA Inc. (NYSE:PHIN) - MarketBeat
FluoRok Raises £7.7M in Funding - FinSMEs
Oxford's FluoRok secures €9.2M from BGF and others - Silicon Canals
HilleVax, Inc. (NASDAQ:HLVX) Given Consensus Rating of “Hold” by Analysts - Defense World
PHINIA Inc. (NYSE:PHIN) Shares Acquired by Long Road Investment Counsel LLC - Defense World
King Luther Capital Management Corp Boosts Position in Helios Technologies, Inc. (NASDAQ:HLIO) - Defense World
Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA) Short Interest Update - Defense World
Hepion Pharmaceuticals faces Nasdaq delisting over share price - Investing.com
Pharma Two B and Hepion Pharmaceuticals file for merger - Investing.com
Pharma Two B and Hepion Pharmaceuticals file for merger By Investing.com - Investing.com UK
Hepion, Pharma Two B file registration statement for proposed merger - TipRanks
Pharma Two B and Hepion Pharmaceuticals, Inc. Announce Filing of Registration Statement on Form F-4 Related to Proposed Merger - ForexTV.com
Hepion Pharmaceuticals (NASDAQ:HEPA) Trading 4.7% Higher - Defense World
TNF Pharmaceuticals (NASDAQ:TNFA) Stock Quotes, Forecast and News Summary - Benzinga
HEPA Stock Earnings: Hepion Pharmaceuticals Reported Results for Q2 2024 - MSN
HEPION PHARMACEUTICALS INC- The GF Score's 5 Key Aspects of Analysis - GuruFocus.com
GSK, Novartis lead July deals as biopharma sector sees more than $20B for the month - BioWorld Online
Hepion Pharmaceuticals announces executive leadership changes - Investing.com India
Hepion Pharmaceuticals announces executive leadership changes By Investing.com - Investing.com UK
Following restructuring, Hepion to merge with Israeli pharma firm - NJBIZ
Cingulate (NASDAQ:CING) Stock Quotes, Forecast and News Summary - Benzinga
HEPA hits 52-week low, trading at 0.7324 USD - Investing.com
HEPA hits 52-week low, trading at 0.7324 USD By Investing.com - Investing.com Canada
Oligonucleotide Therapy Market Targeting the Future of Medicine: Oligonucleotide Therapies Offer Precision ... - WhaTech
Financial Health Check: Examining Hepion Pharmaceuticals Inc (HEPA)’s Key Ratios - The Dwinnex
Aurora Innovation Inc [AUR] Is Currently -0.71 below its 200 Period Moving Avg: What Does This Mean? - The DBT News
Oligonucleotide Therapy Market to Reach USD 19.92 Billion by 2031 | InsightAce Analytic - openPR
The Globe and Mail - The Globe and Mail
Oligonucleotide Therapy Market Transforming Healthcare: - openPR
Hepion Pharmaceuticals Inc’s Banking’s 100-Day Moving Average at 1.6118: Will the Stock Break Through? - The InvestChronicle
The Hepion Pharmaceuticals Inc (HEPA) Stock Is Headed for a Correction - US Post News
IQVIA 'Is A Solid Investment' With Strong Competitive Positioning, Analyst Says After Better Than Expected Q2 Earnings - Markets Insider
Fatty-Liver Focused Hepion Pharmaceuticals Agrees To Merge With Israel-Based Parkinson's Disease Drug Developer - Benzinga
Hepion Pharmaceuticals’ Strategic Merger and Corporate Restructuring - TipRanks
Pharma Two B Announces Plans to Go Public via Merger with Hepion Pharmaceuticals, Inc. and Concurrent $11.5 Million Private Placement - StockTitan
HEPAHepion Pharmaceuticals, Inc. Latest Stock News & Market Updates - StockTitan
Hepion Pharmaceuticals (NASDAQ:HEPA) Stock Quotes, Forecast and News Summary - Benzinga
Biogen Inc. to Post Q2 2024 Earnings of $4.12 Per Share, Leerink Partnrs Forecasts (NASDAQ:BIIB) - American Banking and Market News
Short Interest in Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA) Grows By 58.4% - Defense World
Glencore (OTCMKTS:GLNCY) Stock Price Passes Above Two Hundred Day Moving Average of $11.24 - American Banking and Market News
SEC Form S-1 filed by Hepion Pharmaceuticals Inc. - Quantisnow
BioCryst Pharmaceuticals (NASDAQ:BCRX) Shares Up 6.5% - Defense World
Non-alcoholic Steatohepatitis (MASH) Treatment Market - openPR
Non-Alcoholic Steatohepatitis Pipeline Insight 2024 | Clinical Trials, Latest Approvals, Therapies, Companies | Sagimet ... - Barchart
Non-Alcoholic Steatohepatitis Pipeline Insight 2024 | Clinical Trials, Latest Approvals, Therapies, Companies - openPR
The Emerging Role of Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis - Healio
Is Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA) A Volatile Stock? - Yahoo Canada Shine On
Global Liver Disease Therapeutics Market to Grow Rapidly by 2030, Examines DelveInsight | Key Players in the MarketAbbVie, GSK, F.Hoffmann-La Roche, Bristol-Myers Squibb Company, Abbott, Gilead Sciences, Astellas Pharma - GlobeNewswire
Model Medicines Appoints Dr. Launa Aspeslet as Senior Scientific & Clinical Advisor - PR Newswire
Hepion shelves Phase II NASH trial amid shallow cash resources - Clinical Trials Arena
Why Is Hepion Pharmaceuticals (HEPA) Stock Down 41% Today? - InvestorPlace
Hepion Pharmaceuticals Initiates Wind-Down Activities in Phase 2b ‘ASCEND-NASH’ Trial - StockTitan
Hepion Pharmaceuticals Inc expected to post a loss of $2.63 a shareEarnings Preview - XM
NASH drug market expected to surpass $48B by 2035 - Seeking Alpha
Hepion Pharmaceuticals Appoints Michael Purcell to Board - citybiz
Hepion Pharmaceuticals Bolsters Capital with Equity Deals - TipRanks
Catherine Warren ousted from Edmonton Unlimited - Taproot Edmonton
3.66%
1.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):